The Outcome of Chinese Women With Genitourinary Syndrome of Menopause Treated With Vaginal Dehydroepiandrosterone

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

4 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-01

Study Completion Date

2023-02-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Genitourinary syndrome of menopause (GSM) is a common condition with prevalence was up to 80%. Symptoms associated with GSM include vaginal or vulvar dryness, itchiness, dyspareunia, increased urinary frequency or urgency and dysuria. Although the symptoms are disturbing and causing a significant negative impact on quality of life, it is observed that only a minority of the women receive proper treatment. Treating these GSM-associated symptoms properly is important because these symptoms usually persist with time, unlike vasomotor symptoms of menopause which may subside spontaneously with time.

The clinical efficacy and metabolism of vaginal DHEA has been evaluated in western population. However, there is lack of local data on the effectiveness of vaginal DHEA in treating Chinese women with GSM. Therefore, we aim at evaluating the clinical outcome of our participants who have moderate to severe symptoms of GSM who has been treated with vaginal DHEA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

NCT02013544

Vaginal Atrophy

COMPLETED PHASE3

Evaluation of the Efficacy and Safety of A High Molecular Weight, Natural Hyaluronic Acid Vaginal Gel in Women With Genitourinary Syndrome of Menopause

NCT05263102

Menopause Syndrome

COMPLETED NA

Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause

NCT05483634

Menopause Platelet-rich Plasma Estrogen Replacement Therapy +1 more

NOT_YET_RECRUITING

Local DHEA and Estradiol on Dyspareunia in Postmenopausal Women

NCT05586711

Vulvovaginal Atrophy Genitourinary Syndrome of Menopause

COMPLETED PHASE4

A Clinical Study of Chinese Herbal Formula TJAOA103 in Treating Genitourinary Syndrome of Menopause

NCT07160127

Genitourinary Syndrome of Menopause (GSM)

NOT_YET_RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Genitourinary syndrome of menopause (GSM) is a common condition with prevalence was up to 80%. \[1\] Symptoms associated with GSM include vaginal or vulvar dryness, itchiness, dyspareunia, increased urinary frequency or urgency and dysuria. \[2\] Although the symptoms are disturbing and causing a significant negative impact on quality of life, it is observed that only a minority of the women receive proper treatment. Treating these GSM-associated symptoms properly is important because these symptoms usually persist with time, unlike vasomotor symptoms of menopause which may subside spontaneously with time.

Current treatments for GSM-associated symptoms in our unit at Department of Obstetrics and Gynaecology, Prince of Wales Hospital include vaginal moisturizer and local estrogen- based medications. For vaginal moisturizer, they usually fail to alter the underlying pathophysiological change in urogenital tract. For estrogen-containing treatment, long term use is not recommended as systemic absorption of hormones may occur. A new medication, vaginal dehydroepiandrosterone (DHEA) has been introduced to our unit to treat women with moderate to severe symptoms of GSM since July 2021. The clinical efficacy and metabolism of vaginal DHEA has been evaluated in western population. There were four randomized placebo- controlled studies \[3-6\] showing that 12 weeks treatment of DHEA improved moderate to severe symptoms of GSM. In comparative studies, the efficacy of DHEA was similar to that of conjugated equine estrogen and estradiol. In addition, due to intracrine action of DHEA in particular tissue, it has not showed to increase the level of circulating estrogen or the androgen level beyond the menopausal range. \[7\]

However, there is lack of local data on the effectiveness of vaginal DHEA in treating Chinese women with GSM. Therefore, we aim at evaluating the clinical outcome of our participants who have moderate to severe symptoms of GSM who has been treated with vaginal DHEA.

All Chinese women who have moderate to severe symptoms of GSM and treated with vaginal DHEA since year 2021-2022. All menopause Chinese women with moderate to severe symptoms of GSM and treated with vaginal DHEA were enrolled for analysis. Menopause is defined as cessation of menses for more than 1 year in women with uterus, or follicle stimulating hormone (FSH) ≥ 40 in women with no menses more than 6 months. Diagnosis of GSM was made after exclusion of other differential diagnosis such as candidiasis / lichen sclerosis/ urodynamic stress incontinence/ detrusor over-activity etc. Moderate to severe symptoms of GSM was defined as a visual analogue score (VAS) of 4 or above of any item including vaginal itchiness, dryness, pain and hotness, dysuria, urinary urgency, stress urinary incontinence, urinary urge incontinence and dyspareunia.

There is a standard dataset for patients presenting with GSM is available in the O\&G Department. During the clinic visit, a thorough history and physical examination including abdominal and genital examination will be performed. A transvaginal ultrasound will be performed to determine the endometrial thickness (ET) and exclude other adnexal pathology. Blood taking for hormonal profile was will be performed for baseline check. Mid-stream urinalysis and high vaginal swab will be taken to rule out any infection. After excluding history of hormonal sensitive cancer, active or history of thromboembolic events, unexplained abnormal uterine bleeding and endometrial thickness ≥5mm. If the participant has moderate to severe symptoms of GSM and fit for vaginal DHEA, a 12-week vaginal DHEA will be prescribed. A follow-up appointment will be given in 3-6 months interval to review symptoms. Participants will receive the intervention of vaginal DHEA as a routine medical care.

The medical records of Chinese participants with moderate to severe symptoms of GSM and treated with vaginal DHEA of the aforesaid period will be reviewed. Participant's demographic data, symptoms severity, clinical assessments, investigations, treatment outcome and adverse effect will be collected. The effect of vaginal DHEA will be studied. The end date to the retrospective data collection is 15 Mar 2022.

Genitourinary syndrome of menopause (GSM) is a prevalent but commonly neglected condition. Symptoms can be disturbing to the affected women and affecting their quality of life. The review of the clinical outcome of Chinese women with moderate to severe symptoms of GSM treated with vaginal DHEA allows us to raise awareness of this condition and improve our clinical management. These could also provide a better local evidence of future clinical, research use and patient care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Genitourinary Syndrome of Menopause

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chinese women with moderate to severe symptoms of genitourinary syndrome of menopause

It is a single-group study.

vaginal dehydroepiandrosterone

Intervention Type OTHER

the clinical outcome in Chinese women with moderate to severe symptoms of GSM treated with vaginal DHEA for 12 weeks will be evaluated

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vaginal dehydroepiandrosterone

the clinical outcome in Chinese women with moderate to severe symptoms of GSM treated with vaginal DHEA for 12 weeks will be evaluated

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• All menopause Chinese women who have moderate to severe symptoms of Genitourinary syndrome of menopause (GSM) and treated with vaginal DHEA

Exclusion Criteria

* Genitourinary syndrome of menopause (GSM) due to other differential diagnosis such as candidiasis / lichen sclerosis/urodynamic stress incontinence/ detrusor over-activity.
* Amenorrhoea due to medication
* History of hormonal sensitive cancer, active or history of thromboembolic events, unexplained abnormal uterine bleeding
* Endometrial thickness ≥ 5mm

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No